Originally published In Press as doi:10.1074/jbc.M201444200 on March 29, 2002
J. Biol. Chem., Vol. 277, Issue 24, 22093-22102, June 14, 2002
Mitosis-specific Activation of LIM Motif-containing Protein
Kinase and Roles of Cofilin Phosphorylation and
Dephosphorylation in Mitosis*
Toru
Amano,
Noriko
Kaji,
Kazumasa
Ohashi, and
Kensaku
Mizuno
From the Department of Biomolecular Sciences, Graduate School of
Life Sciences, Tohoku University, Sendai, Miagi 980-8578, Japan
Received for publication, February 12, 2002, and in revised form, March 19, 2002
 |
ABSTRACT |
Actin filament dynamics play a critical
role in mitosis and cytokinesis. LIM motif-containing protein kinase 1 (LIMK1) regulates actin reorganization by phosphorylating and
inactivating cofilin, an actin-depolymerizing and -severing protein. To
examine the role of LIMK1 and cofilin during the cell cycle, we
measured cell cycle-associated changes in the kinase activity of LIMK1
and in the level of cofilin phosphorylation. Using synchronized HeLa cells, we found that LIMK1 became hyperphosphorylated and activated in
prometaphase and metaphase, then gradually returned to the basal level
as cells entered into telophase and cytokinesis. Although Rho-associated kinase and p21-activated protein kinase
phosphorylate and activate LIMK1, they are not likely to be involved in
mitosis-specific activation and phosphorylation of LIMK1. Immunoblot
and immunofluorescence analyses using an anti-phosphocofilin-specific
antibody revealed that the level of cofilin phosphorylation, similar to
levels of LIMK1 activity, increased during prometaphase and metaphase
then gradually declined in telophase and cytokinesis. Ectopic
expression of LIMK1 increased the level of cofilin phosphorylation
throughout the cell cycle and induced the formation of multinucleate
cells. These results suggest that LIMK1 is involved principally in
control of mitosis-specific cofilin phosphorylation and that
dephosphorylation and reactivation of cofilin at later stages of
mitosis play a critical role in cytokinesis of mammalian cells.
 |
INTRODUCTION |
During the cell division cycle, the morphology of cells is
altered. In animal cells in culture, flat and adherent cells in interphase become spherical and weakly adherent in mitosis. At later
stages of mitosis, cortical actin filaments are reorganized and
recruited to the cleavage furrow, and an actomyosin-based contractile
ring is formed around the equator of dividing cells, constricted to
lead to cell cleavage, and disappears at the end of cytokinesis. Actin
filament dynamics, reorganization, and redistribution play a principal
role in these processes (1-3). Previous studies revealed the
involvement of various actin-binding proteins and signaling proteins
that regulate actin filaments in mitotic processes and cytokinesis
(1-3), but mechanisms by which cells coordinately change shapes in
response to cell cycle cues remain largely uncharacterized.
Cofilin and its close relative, actin-depolymerizing factor
(ADF),1 bind to actin
monomers and filaments and play a critical role in regulating actin
filament dynamics and reorganization by stimulating depolymerization
and severance of actin filaments (4-6). The activity of cofilin/ADF is
reversibly regulated by phosphorylation and dephosphorylation at Ser-3,
with the phosphorylated form being inactive (7, 8). LIM kinase 1 (LIMK1) and LIM kinase 2 (LIMK2) (9, 10) phosphorylate cofilin/ADF
specifically at Ser-3 and thereby inhibit actin binding,
depolymerizing, and severing activities of cofilin/ADF (11, 12). LIM
kinases are activated by Rho family small GTPases, Rac, Rho, and Cdc42,
this activation being mediated by downstream effector protein kinases,
such as p21-activated protein kinase (PAK) and Rho-associated kinase
(ROCK), by phosphorylation of Thr-508 of LIMK1 or Thr-505 of LIMK2
(11-18). Previous studies indicated that cofilin phosphorylation by
LIM kinases is a critical signaling event in a variety of
stimulus-induced cell responses, including growth factor-induced
lamellipodium formation, lysophophatidic acid-induced stress fiber
formation, chemokine-induced T cell chemotaxis, semaphorin 3A-induced
neuronal growth cone collapse, and pathogenic bacterium
Listeria-induced phagocytosis (11, 16, 19-22).
In addition to functions in actin cytoskeletal remodeling in interphase
cells, cofilin/ADF seems to be involved in processes related to mitosis
and cytokinesis. Cofilin/ADF is concentrated at the cleavage furrow and
the midbody during cytokinesis of cultured mammalian cells (23) and
cleavage of Xenopus fertilized eggs (24). Injection of the
antibody that inhibits the activity of cofilin/ADF into
Xenopus blastomeres blocks the cleavage of the blastomeres
(24). In addition, Drosophila twinstar mutants, in which
expression of the twinstar gene encoding a
Drosophila cofilin/ADF ortholog is repressed, exhibit
frequent failures in cytokinesis in larval neuroblasts and in
testicular meiotic cells (25). These observations suggest that
cofilin/ADF plays a critical role in cytokinesis. Furthermore,
injection into Xenopus blastomeres of a nonphosphorylatable
(constitutively active) form of cofilin/ADF blocks cytokinesis, but
injection of wild-type cofilin/ADF that can be phosphorylated has no
apparent effect (24), thus indicating that excess activity of
cofilin/ADF also prevents cytokinesis, and the proper control of
cofilin/ADF activity by phosphorylation and dephosphorylation is
important for progression of mitosis. We thus assumed that LIM kinases
play a role in mitosis and cytokinesis by phosphorylating and
regulating the activity of cofilin/ADF.
We have now examined changes in the kinase activity of LIMK1 and the
level of cofilin phosphorylation during the cell cycle, and we found
that LIMK1 becomes activated and hyperphosphorylated in the early
stages of mitosis and then gradually reverts to basal levels in late
stages. Mitotic activation of LIMK1 is induced by a mechanism distinct
from that of Thr-508 phosphorylation by ROCK or PAK. We also noted cell
cycle-associated changes in the level of cofilin phosphorylation which
are similar to those seen with LIMK1 activity. Ectopic expression of
LIMK1 induces increases in the level of cofilin phosphorylation
throughout the cell cycle and leads to the formation of multinucleate
cells. We propose that LIMK1 plays an important role in regulating
cofilin/ADF activity during mitosis and that cofilin dephosphorylation
in the late stages of mitosis is critical for cytokinesis.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Construction--
To generate a pMYC-C1 vector
containing the Myc epitope sequence (EQKLISEEDL), a pEYFP-C1 vector
(CLONTECH, Palo Alto, CA) was digested with
NheI and BglII, and the oligonucleotides coding for Myc epitope peptide were inserted in place of the cDNA for yellow fluorescent protein (YFP). Expression plasmids coding for N-terminally Myc-tagged LIMK1 and LIMK2 were constructed by inserting full-length human LIMK1 and LIMK2 cDNAs (9, 10), respectively, into
the BglII and SacII sites of the pMYC-C1 vector.
Plasmids coding for Myc-LIMK1(D460A) and Myc-LIMK1(T508V), in which
Asp-460 and The-508 in Myc-LIMK1 were replaced by Ala and Val,
respectively, were constructed, using a site-directed mutagenesis
kit (CLONTECH). To construct the
plasmid coding for Myc-LIMK1(PK) containing amino acid residues
267-647, the cDNA fragment was amplified by PCR, using primers
5'-CTAGCTCGCCACCATGGGATACCCATACGATGTTCCAGATTACGCTGGATCCAGATCTGGGCCTGAGACCAGCCCC-3' and 5'-TCCCGCGGAGGAATCTGG-3'. The PCR-amplified
fragments were digested with BglII and
SacII and ligated into the BglII and
SacII sites of the pMYC-C1 vector. The plasmid coding
for LIMK1-YFP was constructed by doubly inserting the PCR-amplified YFP
cDNA into the XbaI and SalI sites of
pMYC-C1-Myc-LIMK1. To construct the plasmid coding for PAK-AI (an
autoinhibitory domain of PAK3, amino acid residues 78-146), the
cDNA fragment was PCR amplified, using primers
5'-CAGAGCGGCCGCATACGATTCATGTGGGGTTT-3' and
5'-GTATGCGGCCGCACTTTTATCTCCTGATGTAA-3', and PAK3 cDNA as a template
(provided by Dr. H. Sumimoto, Kyushu University, Fukuoka, Japan),
digested with NotI, and subcloned into the NotI
site of pCAG vector (17). The authenticity of plasmids was confirmed by
nucleotide sequence analysis.
Cell Culture, Synchronization, and
Transfection--
HeLa cells were cultured in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS).
Cells were synchronized at beginning of the S phase using the double thymidine block method (26, 27). In brief, cells were cultured in DMEM
containing 10% FCS and 1 mM thymidine for 24 h,
incubated in fresh DMEM containing 10% FCS for 8 h, and again
cultured in thymidine-containing medium for 16 h. For cell cycle
progression, cells synchronized at the beginning of S phase were then
released for 6-12 h in fresh DMEM containing 10% FCS. To synchronize
cells at mitosis, cells were synchronized at the beginning of S phase by a single thymidine block and cultured in fresh DMEM containing 10%
FCS for 6 h and then cultured for 6 h in the presence of 100 ng/ml nocodazole. For transient transfection experiments, HeLa cells
were transfected using the LipofectAMINE method (Invitrogen), following
the manufacturer's protocol, cultured in the thymidine-containing medium for 24 h, and released for 6 h in fresh DMEM
containing 10% FCS. Nocodazole, a microtubule-depolymerizing agent,
was added to the medium, and the culture was continued for another
6 h. Mitotic cells that rounded up and adhered weakly on the
culture dish were collected selectively by the mechanical shake-off
procedure, whereas the attached interphase cells were harvested by
scraping them off. To prepare cells synchronized at later stages of
mitosis, mitotic cells collected by nocodazole arrest were washed with phosphate-buffered saline (PBS) to remove nocodazole, suspended in DMEM
containing 10% FCS, plated into poly-L-lysine-coated
culture dishes or coverslips then incubated at 37 °C to allow for
cell cycle progression. At 0, 45, 90, 180 min after release from
nocodazole arrest, the cells were harvested and subjected to analyses.
For flow cytometry, cells were trypsinized, fixed with 70% methanol, stained with propidium iodide, and analyzed by a flow cytometer EPICS
XL-MCL (Beckman Coulter). COS-7 cells were cultured in DMEM supplemented with 10% FCS. Cells were transiently transfected using
LipofectAMINE. Three h after transfection, the medium was changed to
normal cultivation medium. After an additional 36 h culture, cells
were harvested and subjected to analyses.
Antibodies--
Rabbit anti-LIMK1 antibody (C-10) was raised
against the C-terminal peptide of LIMK1, as described (10). An
anti-cofilin antibody (COF-1) was prepared by immunizing rabbits with
His6-cofilin, which was purified from lysates of
Escherichia coli expressing it, using as
nickel-nitrilotriacetic acid-agarose (Qiagen, Valencia, CA). Rabbit
anti-P-cofilin antibody specific to the Ser-3-phosphorylated forms of
cofilin and ADF was raised against the phosphopeptide acetyl-A(pS)GVAVSDC and purified, as described (28). Anti-Myc epitope
monoclonal antibody (9E10) and anti-HA epitope monoclonal antibody
(12CA5) were purchased from Roche Molecular Biochemicals.
Immunoprecipitation--
Cells were washed three times with
ice-cold PBS, suspended in the lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 1 mM dithiothreitol, 10 mM NaF, 20 mM
-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride,
10 µg/ml leupeptin, and 2 µg/ml pepstatin A), and incubated on ice
for 30 min. After centrifugation, protein concentrations in cell
lysates were determined in a Micro BCA protein assay (Pierce), and
equal amounts of protein were precleared with protein A-Sepharose
(Amersham Biosciences) at 4 °C for 1 h. The supernatants were
incubated overnight at 4 °C with anti-LIMK1 (C-10) antibody or 9E10
anti-Myc antibody, and protein A-Sepharose. After centrifugation, the
immunoprecipitates were washed three times with lysis buffer and used
for in vitro kinase reaction and immunoblot analysis.
Immunoblot Analysis--
For immunoblot analysis, cell lysates
or immunoprecipitated proteins were separated on SDS-PAGE and
transferred onto polyvinylidene difluoride membranes (Bio-Rad). The
membrane was blocked overnight with 4% nonfat dry milk in PBS
containing 0.05% Tween 20 and incubated for 2 h at room
temperature with primary antibody diluted in PBS containing 1% nonfat
dry milk and 0.05% Tween 20. After washing in PBS containing 0.05%
Tween 20, the membrane was incubated with horseradish
peroxidase-conjugated donkey anti-rabbit IgG or sheep anti-mouse IgG
(Amersham Biosciences). Immunoreactive protein bands were visualized
using an ECL reagent (Amersham Biosciences).
In Vitro Kinase Assay--
The immunoprecipitates were washed
three times with lysis buffer and then three times with kinase buffer
(20 mM Hepes-NaOH, pH 7.2, 5 mM
MgCl2, 5 mM MnCl2, 1 mM
dithiothreitol, 10 mM NaF, 20 mM
-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, and 2 µg/ml pepstatin A) and incubated for 1 h at 30 °C in 30 µl of kinase buffer containing 50 µM ATP, 5 µCi of [
-32P]ATP (3,000 Ci/mmol, Amersham Biosciences) and 2 µg of His6-cofilin. The reaction mixture was solubilized in Laemmli's sample buffer (50 mM Tris-HCl, pH 6.8, 10% glycerol, 1 mM
dithiothreitol, 1% SDS, 0.002% bromphenol blue) for 5 min at
95 °C, and aliquots were separated on SDS-PAGE, using 15 and 8%
gels. Proteins were transferred onto polyvinylidene difluoride
membranes. The membrane from a 15% gel was subjected to
autoradiography to measure 32P-labeled cofilin, using the
BAS1800 Bio-Image Analyzer (Fuji Film, Tokyo, Japan), and Amido
Black staining. The membrane from the 8% gel was analyzed by
immunoblotting with the C-10 anti-LIMK1 antibody or the 9E10 anti-Myc
antibody to detect LIMK. The kinase activity was normalized by dividing
the radioactivity incorporated into cofilin by the immunoreactive
density of LIMK estimated using a densitometer.
Phosphatase Treatment--
Anti-LIMK1 immunoprecipitates were
washed three times with lysis buffer without phosphatase inhibitors and
then three times with phosphatase buffer (1 mM
MgSO4 and 100 mM Tris-HCl, pH 8.0) and treated
for 1 h at 25 °C with 20 units of calf intestinal alkaline
phosphatase (Takara Biochemicals, Tokyo) in 30 µl of phosphatase
buffer, then the immunoprecipitates were washed three times with lysis
buffer containing phosphatase inhibitors and three times with kinase
buffer and subjected to in vitro kinase reaction, as
described above.
Cell Staining--
HeLa cells were fixed in 4% paraformaldehyde
in PBS for 20 min and permeabilized with absolute methanol for 10 min
at
20 °C. After blocking with 1% bovine serum albumin in PBS for
30 min, cells were stained with anti-P-cofilin antibody followed by
staining with rhodamine-conjugated anti-rabbit IgG (Chemicon). 4,6-Diamidino-2-phenylindole (DAPI, Molecular Probes) was used for DNA
staining. After washing with PBS, coverslips were mounted on a glass
slide and images were obtained using a Leica DMLB fluorescence microscope.
 |
RESULTS |
Mitosis-specific Activation and Phosphorylation of LIMK1--
To
investigate the role of LIMK1 during the cell cycle, we first examined
the kinase activity of LIMK1 in different stages of the cell cycle. For
cell cycle analysis, HeLa cells were synchronized at the beginning of S
phase by double thymidine block. At different times after release from
double thymidine block, cells were lysed, and endogenous LIMK1 was
immunoprecipitated and subjected to in vitro kinase assay,
using His6-cofilin as a substrate. Cell cycle progression
was monitored by flow cytometry (Fig.
1A) and DAPI staining (data
not shown). As shown in Fig. 1B, LIMK1 prepared from cells
at 9 h after release from the thymidine block, when about 40% of
the cells were in mitotic phase (as measured by DAPI staining), had
2.6-fold higher kinase activity than that of LIMK1 from cells at 6 h after release, when about 90% of the cells were in S phase (as
determined using flow cytometry). At 12 h after release, about
80% of the cells had gone through cytokinesis and entered the
G1 phase, and here the kinase activity of LIMK1 reverted to
the level seen in LIMK1 in cells at 6 h. Immunoblot analysis revealed that slow migrating bands of LIMK1 appeared at 9 h,
although the total amount of LIMK1 remained unchanged throughout the
cell cycle.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
Mitosis-specific activation and
phosphorylation of LIMK1. A, HeLa cells were
synchronized at the beginning of S phase by double thymidine block and
released for 6, 9, and 12 h. Cell cycle progression was analyzed
by flow cytometry. B, HeLa cells were synchronized as in
A. At the indicated times after release, cells were lysed,
and endogenous LIMK1 was immunoprecipitated and subjected to in
vitro kinase reaction, using His6-cofilin as a
substrate. The reaction mixture was separated on 15 and 8% SDS-PAGE
and transferred onto polyvinylidene difluoride membranes. Membrane from
the 15% gel was analyzed using autoradiography to detect
32P incorporation into cofilin (top panel) and
by Amido Black staining (second panel from top).
Membrane from the 8% gel was analyzed by immunoblotting with C-10
anti-LIMK1 antibody (third panel). The relative kinase
activity of LIMK1 is shown as the mean ± S.E. of three
independent experiments, with the kinase activity of LIMK1 in cells at
6 h taken as 1.0 (bottom panel). The mean value of the
activity is indicated under the bottom panel. C,
HeLa cells were synchronized at early stages of mitosis by nocodazole
treatment. Interphase (I) and mitotic (M) cells
were selectively collected. The kinase activity and gel mobility of
LIMK1 in interphase and mitotic cells were analyzed as in B. D, effects of phosphatase treatment on kinase activity and
gel mobility of mitotic LIMK1. LIMK1 immunoprecipitated from lysates of
interphase and mitotic cells was incubated with (+) or without ( )
calf intestinal alkaline phosphatase (CIP), and the kinase
activity and gel mobility of LIMK1 were analyzed as in B. In
C and D, the bottom panel shows the
relative kinase activity of LIMK1, with the activity of interphase
LIMK1 without phosphatase treatment taken as 1.0.
|
|
The gel migration shift and activation of LIMK1 became prominent when
cells were more stringently synchronized at the early mitotic phase by
treatment with the microtubule-depolymerizing agent, nocodazole (Fig.
1C). LIMK1 from cells in the early mitotic phase had a
5.8-fold higher kinase activity than in the interphase. Mitotic LIMK1
significantly retarded mobility on gel electrophoresis compared with
interphase LIMK1 (Fig. 1C). To determine whether the
activation and mobility shift of mitotic LIMK1 were related to the
phosphorylation, LIMK1 was treated with calf intestinal alkaline
phosphatase. This treatment abrogated the mobility shift and activation
of mitotic LIMK1 (Fig. 1D). Effects of phosphatase were nil
when phosphatase inhibitors were present (data not shown). These
results suggest that the slow migrating bands are the phosphorylated forms of LIMK1 and that LIMK1 is specifically activated and
phosphorylated in the mitotic phase.
Kinase Activity and Gel Mobility Shift of Kinase-inactive and
N-terminally Truncated LIMK1 Mutants and LIMK2 in Mitosis--
To
search for the mechanism of mitosis-specific activation and gel
mobility shift of LIMK1, Myc-tagged wild-type LIMK1 and its
kinase-inactive mutant LIMK1(D460A), in which the catalytic residue
Asp-460 is replaced by alanine, were transiently expressed in HeLa
cells, and these cells were synchronized at the mitotic phase, using
nocodazole. As shown in Fig.
2A, the transiently expressed
Myc-LIMK1 in mitotic cells showed a gel mobility shift and a 6.4-fold
increase in the kinase activity compared with Myc-LIMK1 in interphase
cells. Thus, the transiently expressed Myc-LIMK1 behaves similarly to
endogenous LIMK1. In both interphase and mitotic cells,
Myc-LIMK1(D460A) immunoprecipitated from HeLa cells exhibited no
cofilin phosphorylating activity, which suggests that Myc-LIMK1
immunoprecipitates were probably not contaminated with other
cofilin-phosphorylating kinases. Similar to Myc-LIMK1, Myc-LIMK1(D460A)
was retarded on gel electrophoresis, which means that
autophosphorylation of LIMK1 may not be involved in mobility shift of
mitotic LIMK1. Myc-LIMK2 transiently expressed in HeLa cells exhibited
a 1.8-fold increase in the kinase activity in mitotic phase, but the
gel mobility shift of Myc-LIMK2 was not visible after cells had been
treated with nocodazole (Fig. 2B). Thus, it is likely that
LIMK2 is at least in part involved in cofilin phosphorylation during
mitosis.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 2.
Kinase activity and gel mobility shift of
transiently expressed LIMK1 mutants and LIMK2 in mitosis.
A, HeLa cells transfected with empty vector
(Mock) or plasmids coding for Myc-tagged wild-type
(WT) LIMK1 or its kinase-inactive D460A mutant were
synchronized, using nocodazole treatment. Lysates of interphase
(I) or mitotic (M) cells were immunoprecipitated
with anti-Myc antibody and subjected to in vitro kinase
reaction. Reaction mixtures were analyzed, as in Fig. 1, by
autoradiography (top panel) and Amido Black staining
(second panel) for cofilin, and immunoblotting with C-10
anti-LIMK1 antibody (third panel). The bottom
panel indicates the relative kinase activity, with the activity of
Myc-LIMK1(WT) in interphase cells taken as 1.0. B, HeLa
cells transfected with plasmids coding for Myc-LIMK2 were synchronized
using nocodazole. Myc-LIMK2 from interphase or mitotic cells was
immunoprecipitated and subjected to in vitro kinase
reaction, and the kinase activity and gel mobility shift were analyzed,
as in A. The bottom panel indicates the relative
kinase activity, with the activity of Myc-LIMK2 in interphase cells
taken as 1.0. C, diagrams of Myc-LIMK1(WT) and its truncated
protein kinase mutant, Myc-LIMK1(PK). LIMK1 contains two LIM domains, a
PDZ domain, and a protein kinase domain. Amino acid residue numbers are
indicated at the top of the diagrams. D, HeLa
cells transfected with plasmids coding for Myc-LIMK1(WT) or
Myc-LIMK1(PK) were synchronized using nocodazole. Myc-LIMK1(WT) and
Myc-LIMK1(PK) from interphase or mitotic cells was immunoprecipitated
and subjected to in vitro kinase reaction, and kinase
activity and gel mobility shift were analyzed, as in A. The
bottom panel indicates the relative kinase activity, with
the activity of Myc-LIMK1(WT) in interphase cells taken as 1.0. In
A, B, and D, experiments were repeated
twice, and similar results were obtained.
|
|
To determine the region involved in the mitosis-specific
phosphorylation and activation of LIMK1, an expression plasmid coding for an N-terminally truncated mutant of LIMK1, Myc-LIMK1(PK) (Fig. 2C), was constructed and transfected into HeLa cells. As
reported (29), in interphase cells, LIMK1(PK) exhibited significant
increases in kinase activity compared with the activity of wild-type
LIMK1 (Fig. 2D). Although the LIMK1(PK) mutant was activated
further by ROCK in in vitro experiments (17), it was not
activated further in mitotic phase, and a gel mobility shift of mitotic
LIMK1(PK) mutant was never observed (Fig. 2D). Thus, the
N-terminal region of LIMK1 containing LIM and PDZ domains may be
involved in the mitosis-specific mobility shift (phosphorylation) and
activation of LIMK1. We attempted to show the gel mobility shift of the
N-terminal fragment of LIMK1 in mitosis, but it was not successful
because the protein band of the fragment expressed in HeLa cells was
not detectable in mitotic cell lysates, probably because of its instability.
Roles of ROCK and PAK in Mitotic Activation of LIMK1--
Previous
studies revealed that LIMK1 is activated by protein kinases, ROCK and
PAK, through phosphorylation at Thr-508 within the kinase domain of
LIMK1 (15-17). We therefore asked whether ROCK and/or PAK is involved
in the activation and mobility shift of LIMK1 in mitosis. To examine
the role of ROCK in this regard, HeLa cells were treated with Y-27632,
a specific inhibitor of ROCK (30), and the activity and gel mobility of
mitotic LIMK1 were analyzed using in vitro kinase assay and
immunoblotting. Gel retardation of mitotic LIMK1 was observed in the
presence of Y-27632 (Fig. 3A).
In vitro kinase assay revealed that the kinase activity of
mitotic LIMK1 was only faintly reduced by Y-27632 treatment (Fig.
3A). Thus, a protein kinase(s) other than ROCK seems to be
involved in the mitosis-specific mobility shift and activation of
LIMK1. We next examined the role of PAK in mitosis-specific activation
and mobility shift of LIMK1. As an inhibitor for PAK, we used an
autoinhibitory domain of PAK (PAK-AI). As reported (15), expression of
PAK-AI inhibited the activation of LIMK1 induced by RacV12, a
constitutively active form of Rac (Fig. 3B), thereby
indicating that PAK-AI has the potential to inhibit PAK activity in
cultured cells. Because the coexpression of PAK-AI and LIMK1 into HeLa
cells did not interfere with mobility shift or activation of LIMK1 in
mitosis (Fig. 3C), PAK does not appear to have a role in
this regard.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of ROCK and PAK inhibitors and
mutation of Thr-508 on the mitosis-specific activation and gel mobility
shift of LIMK1. A, effects of Y-27632 on mitotic
activation of LIMK1. HeLa cells were synchronized using nocodazole in
the absence ( ) or presence (+) of 10 µM Y-27632.
Endogenous LIMK1 from interphase (I) or mitotic
(M) cells was immunoprecipitated and subjected to in
vitro kinase reaction. The kinase activity and gel mobility shift
of LIMK1 were analyzed, as in Fig. 1. The bottom panel
indicates the relative kinase activity, with the activity of interphase
LIMK1 without Y-27632 treatment taken as 1.0. B, effects of
PAK-AI, an inhibitor of PAK, on RacV12-induced activation of LIMK1.
Myc-LIMK1 was coexpressed into COS-7 cells with HA-tagged RacV12 and/or
Myc-tagged PAK-AI, as indicated. LIMK1 was immunoprecipitated with C-10
anti-LIMK1 antibody and subjected to in vitro kinase assay.
Reaction mixtures were analyzed as in A. Expression of
HA-RacV12 and Myc-PAK-AI was analyzed by immunoblotting with anti-HA
(fourth panel) and anti-Myc antibody (fifth
panel), respectively. The bottom panel indicates the
relative kinase activity, with the activity of LIMK1 from cells
transfected with LIMK1 alone taken as 1.0. C, effects of
PAK-AI on mitotic activation of LIMK1. HeLa cells were cotransfected
with plasmids for Myc-LIMK1 and empty vector ( ) or Myc-PAK-AI (+) and
synchronized using nocodazole. Myc-LIMK1 was immunoprecipitated from
interphase or mitotic cells and subjected to in vitro kinase
reaction. The kinase activity and gel mobility shift of LIMK1 were
analyzed, as in A. Expression of Myc-PAK-AI was analyzed by
immunoblotting with an anti-Myc antibody (fourth panel). The
bottom panel indicates the relative kinase activity, with
the activity of interphase Myc-LIMK1 without PAK-AI taken as 1.0. D, effects of Thr-508 mutation on mitotic activation of
LIMK1. HeLa cells transfected with plasmids coding for Myc-LIMK1(WT) or
Myc-LIMK1(T508V) were synchronized by nocodazole treatment.
Myc-LIMK1(WT) and Myc-LIMK1(T508V) from interphase or mitotic cells
were immunoprecipitated and subjected to in vitro kinase
reaction, and their kinase activity and gel mobility shift were
analyzed, as in A. The bottom panel indicates the
relative kinase activity, with the activity of Myc-LIMK1(WT) in
interphase cells taken as 1.0. In A, C, and
D, experiments were repeated twice, and similar results were
obtained.
|
|
To determine further whether phosphorylation of Thr-508 by ROCK, PAK,
or other protein kinases is involved in the mitotic mobility shift and
activation of LIMK1, we expressed in HeLa cells LIMK1(T508V), in which
Thr-508 is replaced by nonphosphorylatable valine, and analyzed its gel
mobility and kinase activity in mitotic phase. Similar to wild-type
LIMK1, LIMK1(T508V) in mitosis migrated slowly on the gel (Fig.
3D), thereby clearly indicating that phosphorylation at
Thr-508 is not related to the mobility shift of mitotic LIMK1 and that
phosphorylation of residue(s) other than Thr-508 is responsible for the
gel retardation. As reported (31), replacing Thr-508 by Val
significantly reduced the kinase activity of LIMK1 (Fig. 3D). However, kinase activity of the LIMK1(T508V) mutant
increased about 3-fold in mitotic phase compared with that in
interphase (Fig. 3D), which further suggests that the
mitotic activation of LIMK1 is caused primarily by mechanisms other
than Thr-508 phosphorylation.
LIMK1 Is Activated in Early Stages of Mitosis--
To examine
further the role of LIMK1 in the mitotic phase, we analyzed changes in
the kinase activity of LIMK1 during mitosis. Nocodazole-arrested
mitotic cells were collected and released for 0, 45, 90, and 180 min to
allow for cell cycle progression. This progression and cell
synchronization were monitored by immunofluorescence microscopy for
tubulin and DNA. Analysis of cell morphology and immunostaining
indicated that almost all of the nocodazole-arrested cells (at zero
time) were in prometaphase. At 45 min after release from nocodazole 70, 20, and 10% of the cells were in metaphase, prometaphase, and
anaphase, respectively; at 90 min, 90 and 5% of the cells in telophase
and anaphase, respectively; and at 180 min, 95% were in G1
phase (data not shown). LIMK1 was immunoprecipitated from the cell
populations at different stages of mitosis and subjected to immunoblot
analysis and in vitro kinase assay (Fig.
4). As described above (Fig.
1B), the kinase activity of LIMK1 at 0 min increased about
5.3-fold compared with that of interphase LIMK1. At 45 min after
nocodazole release, the kinase activity of LIMK1 was retained at a high
level (about 4.8-fold higher than that of interphase LIMK1). LIMK1
activity declined to about 50% of the maximum level at 90 min after
release and reverted to the basal level at 180 min. Immunoblot analysis
revealed that slow migrating forms of LIMK1 were observed at 0 and 45 min after nocodazole release and continued for 90 min. The band of
LIMK1 at 90 min was located halfway between the bands of interphase
LIMK1 and mitotic LIMK1, which suggests that LIMK1 is phosphorylated on multiple sites in early stages of mitosis then gradually
dephosphorylated in the late stage of mitosis. At 180 min, the gel
mobility of LIMK1 was practically identical to that of interphase
LIMK1. These results suggest that LIMK1 is phosphorylated on multiple
sites and highly activated in early stages of mitosis (prometaphase and
metaphase), then dephosphorylated, and reverts back to the basal
activity in later stages of mitosis (telophase and cytokinesis).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 4.
Kinase activity and gel mobility shift of
LIMK1 during the cell cycle. HeLa cells were synchronized using
nocodazole. Endogenous LIMK1 was immunoprecipitated from interphase
cells (I) and cells released for 0, 45, 90, and 180 min
after removal of nocodazole and subjected to in vitro kinase
assay, as in Fig. 1. Relative kinase activity of LIMK1 is shown as the
mean ± S.E. of three independent experiments, with the kinase
activity of LIMK1 in interphase cells taken as 1.0 (bottom
panel).
|
|
Phosphorylation and Dephosphorylation of Cofilin during
Mitosis--
Because LIMK1 specifically phosphorylates cofilin at
Ser-3, we next analyzed the level of cofilin phosphorylation during the cell cycle. The level of cofilin phosphorylation was first measured using immunoblots on two-dimensional gel electrophoresis and an anti-cofilin antibody. As shown in Fig.
5A, the Ser-3-phosphorylated cofilin (P-cofilin) comprises only a small percent of the total amount
of cofilin in interphase HeLa cells. The ratio of P-cofilin increased
in cells in the early stage of mitosis, reached the maximum level
(55%) at 45 min after release from nocodazole arrest, and then
gradually decreased as cells entered into telophase (at 90 min) and
underwent cytokinesis to enter into the G1 phase (at 180 min). Similar results were obtained using one-dimensional gel
immunoblot analysis and an anti-P-cofilin antibody that specifically recognizes the P-cofilin and P-ADF (28) (Fig. 5B, top
panel), in which the total expression level of cofilin remained
unchanged throughout the cell cycle (Fig. 5B, bottom
panel).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 5.
Immunoblot analyses of changes in the level
of cofilin phosphorylation during the cell cycle. HeLa cells were
synchronized using nocodazole. Lysates from interphase cells
(I) and cells released for 0, 45, 90, and 180 min after
removal of nocodazole were separated by two-dimensional gel
electrophoresis (A) or one-dimensional SDS-PAGE on a 15%
gel (B). In A, gels were analyzed by
immunoblotting with an anti-cofilin antibody. Arrowheads
indicate the positions of P-cofilin and cofilin. The ratio of P-cofilin
in total cofilin during the cell cycle is indicated in the bottom
panel. In B, gels were analyzed by immunoblotting with
an anti-P-cofilin antibody (top panel) or an anti-cofilin
antibody (bottom panel). Anti-P-cofilin antibody
specifically recognizes P-cofilin and P-ADF (28).
|
|
The level of cofilin phosphorylation during the cell cycle was examined
further, using asynchronized HeLa cells immunostained with an
anti-P-cofilin antibody. When cell cycle progression of asynchronized
HeLa cells was monitored by cell morphology and DAPI staining, a
significant increase in the level of cofilin phosphorylation was
observed in cells at prometaphase, metaphase, and anaphase but not in
cells at telophase compared with findings with surrounding interphase
cells (Fig. 6). These results provide further evidence that cofilin becomes highly phosphorylated from prometaphase to metaphase then gradually dephosphorylated in the later
stage of mitosis. P-cofilin was localized diffusely in the cytoplasm
throughout mitosis (Fig. 6), whereas cofilin was concentrated in the
cleavage furrow in the late stages of mitosis (23). Because the
phosphorylation of Ser-3 inhibits the actin binding activity of
cofilin, these results suggest that dephosphorylation of cofilin in the
late stages of mitosis correlates with the accumulation of cofilin in
the cleavage furrow in these stages.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 6.
Immunofluorescence analyses of cell
cycle-associated changes in levels of cofilin phosphorylation.
Asynchronized HeLa cells were stained with an anti-P-cofilin antibody
(top panels) and DAPI for DNA (bottom panels).
Arrowheads indicate representative cells in prometaphase,
metaphase, anaphase, and telophase, respectively, as monitored using
DAPI staining. Scale bar, 10 µm.
|
|
Overexpression of LIMK1 Induces Multinucleate
Cells--
Significant changes in the level of cofilin phosphorylation
during mitosis suggest a role for cofilin phosphorylation and dephosphorylation in cell division. To determine whether the
dephosphorylation of cofilin in the later phase of mitosis is required
for cytokinesis, we examined the effects of LIMK1 overexpression on
cell division. For this we constructed an expression plasmid coding for
LIMK1-YFP fusion protein and then transfected it into HeLa cells.
Immunofluorescence analysis using an anti-P-cofilin antibody revealed
that cells expressing LIMK1-YFP showed a significant increase in the
level of cofilin phosphorylation throughout the cell cycle, including telophase and interphase, compared with findings in surrounding nontransfected cells (Fig. 7, top
two horizontal panels). Thus, overexpression of LIMK1 facilitated
increases in levels of cofilin phosphorylation in all stages of the
cell cycle, including the later stages of mitosis. In contrast, in
cells expressing kinase-inactive LIMK1(D460A)-YFP fusion protein (Fig.
7, bottom two lower panels) or control YFP (data not shown),
the level of P-cofilin changed in the cell cycle-dependent
manner, similar to changes seen in nontransfected cells (see Fig. 6),
with the highest level of P-cofilin in metaphase and the low level in
telophase and interphase. Expression of LIMK1(D460A)-YFP reduced the
level of P-cofilin accumulation in metaphase (compare lower two
panels in Fig. 7 with Fig. 6), but the inhibitory effect was
incomplete, which may be attributed to the LIMK2 activity in
mitosis.

View larger version (113K):
[in this window]
[in a new window]
|
Fig. 7.
Expression of LIMK1-YFP, but not of
LIMK1(D460A)-YFP, increases the level of cofilin phosphorylation
throughout the cell cycle. HeLa cells were transiently transfected
with plasmids coding for LIMK1-YFP (first and second
horizontal panels) or LIMK1(D460A)-YFP (third and
fourth horizontal panels). Cells were cultured for 16 h
and immunostained with anti-P-cofilin antibody (second and
fourth horizontal panels). Cells expressing YFP fusion
proteins were visualized by yellow fluorescence (first and
third horizontal panels). Arrowheads indicate the
cells expressing LIMK1-YFP or LIMK1(D460A)-YFP, in interphase,
metaphase, telophase, and later telophase, respectively. Scale
bar, 10 µm.
|
|
When HeLa cells were transfected with plasmids coding for LIMK1-YFP and
cultured for 48 h (a period sufficient for one or two cycles of
cell division), then stained with DAPI, 28% of cells expressing
LIMK1-YFP became multinucleate (Fig. 8,
A and B). Considering that this percentage was
seen after one (or two) cycles of cell division, more than 44% (or
60%) of LIMK1-YFP-expressing cells failed to divide. In contrast, for
cells expressing the LIMK1(D460A)-YFP or the YFP control vector, only a
small percentage of cells had such multinucleate phenotypes (Fig. 8,
A and B). These results suggest that cofilin
phosphorylation by ectopic expression of LIMK1 blocked cytokinesis and
that cofilin dephosphorylation at the later stage of mitosis plays a
critical role in cytokinesis.

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 8.
Overexpression of LIMK1 increases the ratio
of multinucleate cells. A, HeLa cells were transiently
transfected with plasmids coding for control YFP,
LIMK1-YFP, or LIMK1 (D460A)-YFP. Cells were cultured for
48 h, then fixed and stained with DAPI for DNA (bottom
panels). Cells expressing YFP or YFP fusion proteins were
visualized by making use of yellow fluorescence (top
panels). Arrowheads indicate cells expressing YFP or
YFP fusion proteins. Scale bar, 10 µm. B,
quantification of the ratio of multinucleate cells in YFP-positive
cells. Values represent the mean ± S.E. of three independent
experiments.
|
|
 |
DISCUSSION |
Cofilin/ADF plays an essential role in the dynamics of actin
filaments by depolymerizing and severing actin filaments (4-6). In
addition to the roles of cofilin/ADF in cell motility and morphological changes in interphase cells, it is also implicated in mitosis and
cytokinesis (23-25). In Drosophila twinstar mutants, in
which expression of a Drosophila cofilin/ADF gene is
decreased, there are defects in aster migration/separation during
prophase/prometaphase of meiotic divisions of spermatocytes as well as
defects in cytokinesis in mitotic and meiotic cells; large actin
aggregates are detected in association with centrosomes in mature
primary spermatocytes, and during anaphase and telophase aberrantly
large and misshaped actin structures appear at the site of contractile
ring formation. These structures fail to disassemble at the end of
telophase (25). These in vivo analyses suggest that
cofilin/ADF plays important roles both in centrosome movement in early
stages of mitosis and in contractile ring formation, constriction,
and/or disassembly during later stages of mitosis/meiosis and
cytokinesis. The role of cofilin/ADF in cytokinesis is also suggested
by observations that cofilin/ADF accumulates at the contractile ring
and midbody during later stages of mitosis in Xenopus eggs
and in mammalian cells undergoing cytokinesis (23, 24) and that
inhibition of cofilin/ADF activity in Xenopus blastomeres by
injection of an inhibitory antibody blocks cytokinesis yet without
inhibiting nuclear division (24). In addition, the role of cofilin/ADF in centrosome migration and/or spindle formation in early stages of
meiosis is suggested by the observation that cofilin/ADF inactivation by overexpression of LIMK in progesterone-treated Xenopus
oocytes inhibits formation of the white maturation spot, which
indicates entry into meiosis, and impairs the organization and
migration of the microtubule organizing center and transient
microtubule array (32). Thus, cofilin/ADF probably plays a role in
centrosome movement and contractile ring formation and/or disassembly
by regulating actin filament dynamics and reorganization, but precise mechanisms remain to be determined.
In the present study, we noted changes in the level of cofilin
phosphorylation during the cell cycle; it gradually increases in early
stages of mitosis, peaks at metaphase, and then gradually decreases in
telophase and cytokinesis, findings consistent with data that in
Xenopus eggs cofilin/ADF is hyperphosphorylated at metaphase
II arrest and dephosphorylated after fertilization (24). Because
cofilin/ADF activity is depressed by phosphorylation at Ser-3, the
content of active cofilin/ADF is high in interphase and at the onset of
mitotic phase, lowers from prometaphase to metaphase, and augments
during telophase and cytokinesis. Cell cycle-associated changes in the
level of cofilin phosphorylation seem to correlate with functional
roles of cofilin/ADF in centrosome migration and separation in the
entry stage of mitosis and in contractile ring formation and/or
disassembly in later stages of mitosis and cytokinesis. We found that
ectopic expression of LIMK1 increases the level of cofilin
phosphorylation throughout the cell cycle and induces production of
multinucleate cells, an event probably caused by aberrant
phosphorylation and inactivation of cofilin/ADF in later stages of
mitosis. Thus, dephosphorylation and reactivation of cofilin/ADF in
later stages of mitosis are probably critical for cytokinesis. Because
S3D-cofilin, with replacement of Ser-3 by Asp and which mimics the
phosphorylated form of cofilin, does not accumulate on the contractile
ring in late stages of mitosis, dephosphorylation is also required to
localize cofilin/ADF onto the cleavage furrow where it functions (33).
Additionally, injection into Xenopus blastomeres of a
nonphosphorylatable (constitutively active) mutant of cofilin/ADF
destroys the contractile ring and regresses the cleavage furrow (24);
hence, excess activity of cofilin/ADF is probably harmful for cell
division. Thus, the cofilin/ADF activity must be controlled precisely
during the cell cycle by phosphorylation and dephosphorylation for
cells to proceed to mitosis and cytokinesis.
The kinase activity of LIMK1 changes significantly during the cell
cycle, the highest activity being in prometaphase and metaphase, which
is similar to changes in levels of cofilin phosphorylation. However,
the level of cofilin phosphorylation peaks at metaphase, whereas the
kinase activity of LIMK1 in prometaphase is slightly higher than that
in metaphase. This difference is probably the result of differences in
cofilin phosphatase activity during the cell cycle because the level of
this phosphorylation is probably regulated by the balance between
activities of cofilin kinase and phosphatase. Niwa et al.
(34) recently identified a novel family of protein phosphatases, termed
"Slingshot," which specifically dephosphorylates cofilin/ADF at
Ser-3 in vitro and in vivo (34). Determination of
changes in the activity of Slingshot phosphatase during the cell cycle
will be important to elucidate further the mechanisms by which
cofilin/ADF activity is regulated during the cell cycle. Although
testicular protein kinase 1, which contains a protein kinase domain
similar to those of LIMKs, also phosphorylates cofilin/ADF specifically
at Ser-3 (28), the kinase activity of TESK1 did not change during the
cell cycle.2 We show in this
study that the kinase activity of LIMK2 increases slightly in mitosis.
Expression of a kinase-negative LIMK1 did not completely inhibit
P-cofilin accumulation in metaphase, which may suggest that LIMK2 also
contributes to some extent to the mitosis-specific cofilin
phosphorylation. Thus, it appears that LIMK1 and in part LIMK2 are
responsible for the phosphorylation of cofilin/ADF during mitosis.
Previous studies revealed that LIMK1 is activated by ROCK and PAK,
downstream effectors of Rho and Rac, respectively, through phosphorylation of Thr-508 within the PK domain of LIMK1 (15-17). However, the present study revealed that the mitotic activation of
LIMK1 is not inhibited by Y-27632 (a specific inhibitor of ROCK) or by
PAK-AI (an autoinhibitory peptide for PAK), which suggests that neither
the Rho-ROCK nor the Rac-PAK signaling pathway is involved in the
mitotic activation of LIMK1. Although Rho and ROCK are activated during
mitosis and were shown to be critical for cytokinesis (3, 27, 35-37),
the time courses of activation of LIMK1 and Rho during mitosis
significantly differ; activation of LIMK1 peaks at prometaphase and
metaphase, whereas activation of Rho peaks in telophase (27). These
findings further suggest that mitotic activation of LIMK1 is
independent of the Rho-ROCK signaling pathway.
We have found that the LIMK1(T508V) mutant, in which Thr-508 is
replaced by a nonphosphorylatable Val residue, is also retarded on gel
electrophoresis and activated in mitotic cells, which further suggests
that mitotic activation of LIMK1 is caused by a mechanism distinct from
the phosphorylation of Thr-508. Interestingly, mitosis-specific activation and gel mobility shift of LIMK1 are abolished by deleting the N-terminal half region of LIMK1. Thus, the N-terminal region may be
involved in the mitotic activation and phosphorylation of LIMK1. In
this respect, we showed previously that the N-terminal LIM domain
regulates the kinase activity of LIMK1 negatively by direct interaction
with the C-terminal PK domain (29). It may be that mitotic LIMK1 is
activated by phosphorylation of the N-terminal region, by which the
conformational change is induced to activate the C-terminal catalytic
domain by releasing it from restraint of the N-terminal region.
Because we detected at least two distinct retarded bands of LIMK1
during mitosis, mitotic LIMK1 is probably phosphorylated on multiple
sites. The protein kinase(s) that is responsible for mitotic activation
of LIMK1 has yet to be identified. Potential candidates for
LIMK1-activating protein kinases include Cdc2 kinase, mitogen-activated
protein kinase (MAPK), or other kinases that are activated in early
stages of mitosis (38, 39). Human LIMK1 carries in the N-terminal half
region nine (Ser/Thr)-Pro sequences, and these are canonical
phosphorylation sites catalyzed by Cdc2 kinase and MAPK. Indeed, both
Cdc2 kinase and MAPK were able to phosphorylate LIMK1, but neither Cdc2
kinase nor MAPK induced gel mobility shift or activation of LIMK1 in
in vitro experiments.2 Furthermore, mitotic
LIMK1 did not immunoreact significantly with MPM-2 antibody, which
specifically recognizes phospho-Ser/Thr-Pro sequences
(40).2 Thus, it is most likely that protein kinase(s) other
than Cdc2 kinase and MAPK are involved in the mitotic activation and
the gel mobility shift of LIMK1, although it is still possible that these kinases have a partial role in the mitotic activation of LIMK1.
To define the molecular basis of the cell cycle-associated activation
of LIMK1, in future studies we will search for the responsible protein
kinases and the residues phosphorylated on mitotic LIMK1.
By way of summary we obtained evidence for the mitosis-specific
activation and hyperphosphorylation of LIMK1. The mitotic activation of
LIMK1 is apparently not related to the Rho-ROCK or Rac-PAK pathway.
These findings suggest a novel mechanism of LIMK1 activation and novel
cellular functions of LIMK1 and cofilin in the mitotic phase, in
addition to their functions in cell motility and morphology in interphase.
 |
ACKNOWLEDGEMENTS |
We thank Dr. K. Nagata-Ohashi and M. Yamamoto (Tohoku University) for antibody preparation, Dr. H. Sumimoto (Kyushu University) for providing PAK3 cDNA, Drs. K. Hayashi and M. Satake (Tohoku University) for flow cytometric analysis,
Drs. T. Hirota and H. Saya (Kumamoto University) and Dr. Y. Fujiki
(Kyushu University) for helpful advice, and M. Ohara for language assistance.
 |
FOOTNOTES |
*
This work was supported by a grant-in-aid for creative
scientific research from the Japan Society of the Promotion of Science and a grant-in-aid for scientific research from the Ministry of Education, Science, Technology, Sports, and Culture of Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Biomolecular Sciences, Graduate School of Life Sciences, Tohoku
University, Aramaki-aza-Aoba, Aoba-ku, Sendai, Miagi 980-8578, Japan. Tel.: 81-22-217-6676; Fax: 81-22-217-6678; E-mail:
kmizuno@biology.tohoku.ac.jp.
Published, JBC Papers in Press, March 29, 2002, DOI 10.1074/jbc.M201444200
2
T. Amano, N. Kaji, K. Ohashi, and K. Mizuno,
unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
ADF, actin-depolymerizing factor;
AI, autoinhibitory domain;
DAPI, 4,6-diamidino-2-phenylindole;
DMEM, Dulbecco's modified Eagle's
medium;
FCS, fetal calf serum;
LIMK, LIM motif-containing protein
kinase;
MAPK, mitogen-activated protein kinase;
P-cofilin, Ser-3-phosphorylated cofilin;
PAK, p21-activated protein kinase;
PBS, phosphate-buffered saline;
PK domain, protein kinase domain;
ROCK, Rho-associated kinase;
WT, wild-type;
YFP, yellow fluorescent
protein.
 |
REFERENCES |
| 1.
|
Fishkind, D. J.,
and Wang, Y. L.
(1995)
Curr. Opin. Cell Biol.
7,
23-31[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Robinson, D. N.,
and Spudich, J. A.
(2000)
Trends Cell Biol.
10,
228-237[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Prokopenko, S. N.,
Saint, R.,
and Bellen, H. J.
(2000)
J. Cell Biol.
148,
843-848[Abstract/Free Full Text]
|
| 4.
|
Moon, A.,
and Drubin, D. G.
(1995)
Mol. Biol. Cell
6,
1423-1431[Medline]
[Order article via Infotrieve]
|
| 5.
|
Bamburg, J. R.
(1999)
Annu. Rev. Cell Dev. Biol.
15,
185-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Pantaloni, D., Le,
Clainche, C.,
and Carlier, M.-F.
(2001)
Science
292,
1502-1506[Abstract/Free Full Text]
|
| 7.
|
Agnew, B. J.,
Minamide, L. S.,
and Bamburg, J. R.
(1995)
J. Biol. Chem.
270,
17582-17587[Abstract/Free Full Text]
|
| 8.
|
Moriyama, K.,
Iida, K.,
and Yahara, I.
(1996)
Genes Cells
1,
73-86[Abstract]
|
| 9.
|
Mizuno, K.,
Okano, I.,
Ohashi, K.,
Nunoue, K.,
Kuma, K.,
Miyata, T.,
and Nakamura, T.
(1994)
Oncogene
9,
1605-1612[Medline]
[Order article via Infotrieve]
|
| 10.
|
Okano, I.,
Hiraoka, J.,
Otera, H.,
Nunoue, K.,
Ohashi, K.,
Iwashita, S.,
Hirai, M.,
and Mizuno, K.
(1995)
J. Biol. Chem.
270,
31321-31330[Abstract/Free Full Text]
|
| 11.
|
Yang, N.,
Higuchi, O.,
Ohashi, K.,
Nagata, K.,
Wada, A.,
Kangawa, K.,
Nishida, E.,
and Mizuno, K.
(1998)
Nature
393,
809-812[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Arber, S.,
Barbayannis, F. A.,
Hanser, H.,
Schneider, C.,
Stanyon, C. A.,
Bernard, O.,
and Caroni, P.
(1998)
Nature
393,
805-809[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Chernoff, J.
(1999)
Nat. Cell Biol.
1,
E115-E117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Sumi, T.,
Matsumoto, K.,
Takai, Y.,
and Nakamura, T.
(1999)
J. Cell Biol.
147,
1519-1532[Abstract/Free Full Text]
|
| 15.
|
Edwards, D. C.,
Sanders, L. C.,
Bokoch, G. M.,
and Gill, G. N.
(1999)
Nat. Cell Biol.
1,
253-259[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Maekawa, M.,
Ishizaki, T.,
Boku, S.,
Watanabe, N.,
Fujita, A.,
Iwamatsu, A.,
Obinata, T.,
Ohashi, K.,
Mizuno, K.,
and Narumiya, S.
(1999)
Science
285,
895-898[Abstract/Free Full Text]
|
| 17.
|
Ohashi, K.,
Nagata, K.,
Maekawa, M.,
Ishizaki, T.,
Narumiya, S.,
and Mizuno, K.
(2000)
J. Biol. Chem.
275,
3577-3582[Abstract/Free Full Text]
|
| 18.
|
Amano, T.,
Tanabe, K.,
Eto, T.,
Narumiya, S.,
and Mizuno, K.
(2001)
Biochem. J.
354,
149-159[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Zebda, N.,
Bernard, O.,
Bailly, M.,
Welti, S.,
Lawrence, D. S.,
and Condeelis, J. S.
(2000)
J. Cell Biol.
151,
1119-1128[Abstract/Free Full Text]
|
| 20.
|
Nishita, M.,
Aizawa, H.,
and Mizuno, K.
(2002)
Mol. Cell. Biol.
22,
774-783[Abstract/Free Full Text]
|
| 21.
|
Aizawa, H.,
Wakatsuki, S.,
Ishii, A.,
Moriyama, K.,
Sasaki, Y.,
Ohashi, K.,
Sekine-Aizawa, Y.,
Sehara-Fujisawa, A.,
Mizuno, K.,
Goshima, Y.,
and Yahara, I.
(2001)
Nat. Neurosci.
4,
367-373[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Bierne, H.,
Gouin, E.,
Roux, P.,
Caroni, P.,
Yin, H. L.,
and Cossart, P.
(2001)
J. Cell Biol.
155,
101-112[Abstract/Free Full Text]
|
| 23.
|
Nagaoka, R.,
Abe, H.,
Kusano, K.,
and Obinata, T.
(1995)
Cell Motil. Cytoskeleton
30,
1-7[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Abe, H.,
Obinata, T.,
Minamide, L. S.,
and Bamburg, J. R.
(1996)
J. Cell Biol.
132,
871-885[Abstract/Free Full Text]
|
| 25.
|
Gunsalus, K. C.,
Bonaccorsi, S.,
Williams, E.,
Verni, F.,
Gatti, M.,
and Goldberg, M. L.
(1995)
J. Cell Biol.
131,
1243-1259[Abstract/Free Full Text]
|
| 26.
|
Hirota, T.,
Morisaki, T.,
Nishiyama, Y.,
Marumoto, T.,
Tada, K.,
Hara, T.,
Masuko, N.,
Inagaki, M.,
Hatakeyama, K.,
and Saya, H.
(2000)
J. Cell Biol.
149,
1073-1086[Abstract/Free Full Text]
|
| 27.
|
Kimura, K.,
Tsuji, T.,
Takada, Y.,
Miki, T.,
and Narumiya, S.
(2000)
J. Biol. Chem.
275,
17233-17236[Abstract/Free Full Text]
|
| 28.
|
Toshima, J.,
Toshima, J. Y.,
Amano, T.,
Yang, N.,
Narumiya, S.,
and Mizuno, K.
(2001)
Mol. Biol. Cell
12,
1131-1145[Abstract/Free Full Text]
|
| 29.
|
Nagata, K.,
Ohashi, K.,
Yang, N.,
and Mizuno, K.
(1999)
Biochem. J.
343,
99-105
|
| 30.
|
Uehata, M.,
Ishizaki, T.,
Satoh, H.,
Ono, T.,
Kawahara, T.,
Morishita, T.,
Tamakawa, H.,
Yamagami, K.,
Inui, J.,
Maekawa, M.,
and Narumiya, S.
(1997)
Nature
389,
990-994[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Edwards, D. C.,
and Gill, G. N.
(1999)
J. Biol. Chem.
274,
11352-11361[Abstract/Free Full Text]
|
| 32.
|
Takahashi, T.,
Koshimizu, U.,
Abe, H.,
Obinata, T.,
and Nakamura, T.
(2001)
Dev. Biol.
229,
554-567[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Nagaoka, R.,
Abe, H.,
and Obinata, T.
(1996)
Cell Motil. Cytoskeleton
35,
200-209[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Niwa, R.,
Nagata-Ohashi, K.,
Takeichi, M.,
Mizuno, K.,
and Uemura, T.
(2002)
Cell
108,
233-246[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Mabuchi, I.,
Hamaguchi, Y.,
Fujimoto, H.,
Morii, N.,
Mishima, M.,
and Narumiya, S.
(1993)
Zygote
1,
325-331[Medline]
[Order article via Infotrieve]
|
| 36.
|
Kishi, K.,
Sasaki, T.,
Kuroda, S.,
Itoh, T.,
and Takai, Y.
(1993)
J. Cell Biol.
120,
1187-1195[Abstract/Free Full Text]
|
| 37.
|
Kosako, H.,
Yoshida, T.,
Matsumura, F.,
Ishizaki, T.,
Narumiya, S.,
and Inagaki, M.
(2000)
Oncogene
19,
6059-6064[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Pines, J.
(1999)
Nat. Cell Biol.
1,
E73-E79[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Takenaka, K.,
Gotoh, Y.,
and Nishida, E.
(1997)
J. Cell Biol.
136,
1091-1097[Abstract/Free Full Text]
|
| 40.
|
Davis, F. M.,
Tsao, T. Y.,
Fowler, S. K.,
and Rao, P. N.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
2926-2930[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. Ross-Macdonald, H. de Silva, Q. Guo, H. Xiao, C.-Y. Hung, B. Penhallow, J. Markwalder, L. He, R. M. Attar, T.-a. Lin, et al.
Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors
Mol. Cancer Ther.,
November 1, 2008;
7(11):
3490 - 3498.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Horita, K. Ohashi, M. Mukai, M. Inoue, and K. Mizuno
Suppression of the Invasive Capacity of Rat Ascites Hepatoma Cells by Knockdown of Slingshot |